Edition:
United Kingdom

Array Biopharma Inc (ARRY.OQ)

ARRY.OQ on NASDAQ Stock Exchange Global Market

15.97USD
14 Dec 2018
Change (% chg)

$0.11 (+0.69%)
Prev Close
$15.86
Open
$15.71
Day's High
$16.34
Day's Low
$15.50
Volume
844,689
Avg. Vol
732,967
52-wk High
$20.20
52-wk Low
$10.54

Chart for

About

Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer. The Company's programs include approximately three cancer drugs, binimetinib, encorafenib and selumetinib (partnered with AstraZeneca, PLC). Its... (more)

Overall

Beta: 1.99
Market Cap(Mil.): $2,368.37
Shares Outstanding(Mil.): 192.24
Dividend: --
Yield (%): --

Financials

  ARRY.OQ Industry Sector
P/E (TTM): -- 69.71 34.39
EPS (TTM): -0.72 -- --
ROI: -71.65 9.01 14.96
ROE: -- 10.15 16.52

Array BioPharma gets FDA nod for melanoma combo treatment

The U.S. Food and Drug Administration said on Wednesday it approved Array BioPharma Inc's oral combination treatment for use in patients with the deadliest form of skin cancer.

27 Jun 2018

UPDATE 2-Array BioPharma gets FDA nod for melanoma combo treatment

June 27 The U.S. Food and Drug Administration said on Wednesday it approved Array BioPharma Inc's oral combination treatment for use in patients with the deadliest form of skin cancer.

27 Jun 2018

CORRECTED-UPDATE 1-FDA approves Array BioPharma's melanoma combo treatment

June 27 The U.S. Food and Drug Administration (FDA) said on Wednesday it had approved Array BioPharma Inc's oral combination treatment for use in patients with the deadliest form of skin cancer.

27 Jun 2018

CORRECTED-Array's melanoma combo treatment wins FDA approval

June 27 The U.S. Food and Drug Administration said on Wednesday it had approved Array BioPharma Inc's combination treatment for use in patients with the deadliest form of skin cancer.

27 Jun 2018

Earnings vs. Estimates